OR WAIT null SECS
A discussion of the recent research on the use of antidepressants in bipolar disorder (BD), and the methodologic principles that should guide this aspect of psychopharmacology.
The Islamic philosopher and physician Abu'l-Walid Ibn Rushd, better known as Averroës, said that the art of healing requires "the acquisition of universal principles . . . coupled with prolonged experience."1 In this article, we review some of the recent research on the use of antidepressants in bipolar disorder (BD), and we also discuss briefly the methodologic principles that should guide us in this aspect of psychopharmacology. Our sense is that differing approaches to this controversial practice stem more from differences in methodologic assumptions (Averroës's "universal principles") than from differences in the research studies themselves.2
Most clinicians prescribe antidepressants extensively in the treatment of BD. In one study, antidepressants had been prescribed for more than 80% of patients with BD, but only 55% had received mood stabilizers, and only one third had ever been given mood stabilizer monotherapy.3
In the world of academic research 2 basic perspectives have been laid out: that antidepressants are effective and largely safe,4 and that antidepressants are largely ineffective and mostly unsafe.5 There is evidence for and against each of these perspectives.
While there might be a misperception that the debate is about whether to use antidepressants at all in BD, no expert denies that antidepressants have some role in managing this condition. The questions regarding antidepressant use in BD involve the frequency of their use, for which kinds of patients they should be used, and under what circumstances they should be used.6
A key feature of evidence-based medicine is the concept of levels of evidence (Table 1 [please see Psychiatric Times, May 2006, page 66]).2,7 Levels of evidence provide clinicians and researchers with a road map that allows consistent and justified comparison of different studies to adequately compare and contrast their findings.
The key point to keep in mind is that each level of evidence has its own strengths and weaknesses, and as a result, no single level is completely useful or useless. For example, metaanalyses and large randomized studies may obscure subtle differences among subgroups. Other variables being equal, increasing rigor and probable scientific accuracy occur as one moves from level V to level I.
The recognition of levels of evidence allows one to have a guiding principle by which to assess the literature. The basic rules are:
The key reason that randomized studies are more valid than nonrandomized or observational studies is confounding bias, which is systematic error (as opposed to the random error of chance). "Confounding" means that there is some other factor, besides the factor one thinks is at issue, that explains the result (Figure); confounding bias is always a potential problem with any observational study. Observational studies are conducted under normal clinical conditions: a physician decides to give certain treatments for specific patients. Confounding bias can only be removed by designing a randomized study, or, in the case of observational studies, by a statistical analysis that involves regression models.8
In assessing recent studies, we will keep our focus on the concepts of levels of evidence and confounding bias. Regarding antidepressants and BD, 5 studies in the past 2 years stand out, 3 of which are published and 2 of which are quite new and as yet unpublished (Table 2).
This study assessed 84 patients who had responded to an antidepressant plus a mood stabilizer for acute bipolar depression9; after acute recovery, those who continued to take the combination stayed well longer in the 1-year follow-up than those in whom antidepressant therapy was stopped after the acute episode resolved. In other words, the study seems to show that long-term continuation of antidepressants in BD appears to lead to better outcomes. Yet, the study is observational, not randomized, and thus liable to confounding bias. Its level of evidence is III.
Readers can begin to assess this issue by putting themselves in the place of the treating clinicians. Why would one stop an antidepressant after acute recovery? Some literature suggests that antidepressants can cause or worsen rapid cycling in patients with BD; so if a patient has rapid-cycling illness, some clinicians would be inclined to stop the antidepressant after acute recovery. If a patient had a history of incidents of antidepressant-induced mania that were frequent or severe, some clinicians might not continue the antidepressant. Perhaps if the patient had BD type I, some clinicians would be less likely to continue antidepressants than if the patient had BD type II. These are issues of selection bias or so-called confounding by indication: the physician decides what to do nonrandomly.
There also may be other confounders; for example, there may be more males, a younger age at onset, or a greater severity of illness in 1 group. If there were more patients with rapid cycling in the group that discontinued antidepressants than in the group that continued antidepressant treatment, this would be confounding by indication. As a result, the observed finding that the group that discontinued antidepressant treatment relapsed before the other group would be explained by the natural history of rapid-cycling illness: patients with rapid cycling relapse more rapidly than those who do not experience rapid cycling.
It may not be, in fact, that any of these potential confounders actually influenced the results of the study. However, the authors did not conduct any statistical analyses (eg, regression models) to assess and correct for confounding factors. In response to a letter to the editor,10 for instance, they indicated that no patients in the study had rapid-cycling BD, which would have been a major potential confounding factor. The absence of such patients indicates that no one with rapid-cycling BD responded to acute treatment with antidepressants, which is itself an interesting observation, since the original cohort did not exclude rapid cyclers. Furthermore, if the data are accepted as valid, despite their observational nature, they only generalize to about 15% of the patients treated with antidepressants for acute bipolar depression, since 85% of the patients either failed to respond sufficiently to enter the study or they experienced manic switches.
This study has since been replicated by Joffe and colleagues11 with 59 patients. Again, in the same observational design, if patients responded to an antidepressant plus mood stabilizer, they then stayed well longer if they continued to take the combination.
Here the concept of confounding bias is relevant; since bias is systematic (not random) error, if a study influenced by confounding bias is designed the same way, the same erroneous result will be found. The concept of replication is only relevant to an unbiased study, such as one completed with randomized data; hence, it is not surprising to find the same systematically biased results from a repetition of the same observational design. The validity of the results would be better established by randomized study designs.
Gijsman and colleagues12 published an important meta-analysis of placebocontrolled randomized studies of antidepressant efficacy in acute bipolar depression. Based on the 5 studies that were identified, the authors found that antidepressants were more effective than placebo. Further, in those same 5 studies, there was no evidence of an incidence of antidepressant-induced manic episodes beyond that which was observed with placebo. The authors thus concluded that antidepressants are effective and safe in bipolar depression, based on the most rigorous available data.
In terms of interpretation, it is worth noting that a meta-analysis represents an observational study of studies. A meta-analysis of 5 randomized clinical trials is not necessarily more valid than 1 well-designed, randomized clinical trial, because the benefits of random assignment and the removal of confounding bias within a sample are lost in a meta-analysis; this results in the problem of heterogeneity between study samples. One may believe this issue to be less relevant if study results agree (as it appears they did in this meta-analysis), but this apparent agreement hides important unexplored heterogeneity. While this heterogeneity does not invalidate the meta-analysis, it can lead to its misinterpretation.
The 5 studies in the meta-analysis contain the following heterogeneity:
The 2001 study by Nemeroff and colleagues13 was the only placebocontrolled study that found no evidence of acute antidepressant response (all patients received baseline lithium). Another study nonrandomly assigned lithium to 37% of the patients in the antidepressant group, but only 21% in the placebo group.14 This is about a 77% increase in lithium use among the antidepressant group-hardly a fair assessment of fluoxetine versus placebo.
Two other studies compared antidepressant alone with placebo alone, and 1 large study (58.5% of all meta-analysis patients) compared olanzapine plus fluoxetine with olanzapine alone (the term "placebo" was used improperly to refer to olanzapine plus placebo).15 Thus, the authors of the meta-analysis interpreted data from a comparison of olanzapine/fluoxetine combination with olanzapine plus placebo, but interpreted the data as a comparison of fluoxetine with placebo (by simply canceling out or ignoring the olanzapine component). However, olanzapine is not an inert substance and thus cannot be ignored; this is another source of heterogeneity for the overall meta-analysis.
While these studies may suggest acute antidepressant efficacy compared with no treatment or olanzapine alone, they do not address the most relevant clinical issue of acute antidepressant efficacy when compared with lithium, the most proven mood stabilizer.
With regard to antidepressantinduced mania, 2 studies comparing antidepressants alone with placebo alone strangely reported no mania in any patients. This is an oddity, if true, because it would suggest either that even spontaneous mania did not occur during the study or that perhaps manic symptoms were not adequately assessed. As described above, another study preferentially prescribed lithium more in the antidepressant group,14 possibly providing unequal protection against mania.
Although the olanzapine/fluoxetine data suggest no evidence of switching while using antipsychotics, our re-analysis of the lithium-plus-paroxetine (or imipramine) study indicated that the manic-switching rate was 3 times higher with imipramine than with placebo (risk ratio, 3.14), with asymmetrically positively skewed confidence intervals (0.34 to 29.0). When combined with other studies that showed higher switching rates with tricyclic antidepressants than with other antidepressants, this heterogeneity suggests that antidepressant switching cannot be ruled out.
It also should be noted that these short-term (up to 10 weeks) studies are relevant only for the acute depressive episode, if they are relevant at all. They do not provide any evidence in support of the long-term maintenance use of antidepressants in BD. In fact, a previous systematic review of multiple randomized clinical trials found such use to be ineffective.16
In summary, our critique touches not only on the validity of the meta-analysis by Gijsman and associates12 but also on its generalizability as a result of unexplored heterogeneity. Major conflicting results between one adequately designed study using lithium and the remaining studies are hidden by the apparent overall agreement among the studies. These positive conclusions of the meta-analysis appear to be premature when clinical options involve the use of proven mood stabilizers, such as lithium, with or without antidepressants.
The Stanley Foundation Network has also just analyzed the results of an acute and maintenance treatment study of bipolar depression, in which 159 patients with acute depression (in 228 treatment trials) were randomly selected to receive venlafaxine, sertraline, or bupropion, added to standard mood stabilizers, with double-blind treatment for 1 year.17 The results demonstrated similar acute response and remission rates, with acute response occurring in about 50% of patients and acute remission occurring in about 30% of patients. (Acute response was defined as a 50% decline in depressive rating scores at 8 weeks, and acute remission was defined as minimal absolute final depressive rating scores at 8 weeks.)
The absence of a placebo group prevents one from being certain that such benefit is better than natural history, although clinical experience would suggest that it may be. Acute manic switch rates were much higher with venlafaxine than with the other agents at 8 weeks (30.3% with venlafaxine vs 14% to 15% with bupropion or sertraline) (Robert M. Post, MD, personal communication, 2006); relative risk and confidence intervals, in our calculation of an earlier presentation of this dataset, were 2.08 (1.00, 4.36) for increased risk with velafaxine. At 1-year follow-up, the remission rates (without any manic/ hypomanic switch) had declined to only about 16.3% of the whole sample, and longer-term switch rates continued to accumulate with all 3 agents.
Again, the absence of a placebo group prevents one from definitively attributing those manic switches to the antidepressants, or from concluding that the 16% 1-year remission rate is more than what would have occurred by natural history. Nonetheless, this study agrees with the earlier Stanley Foundation study9 in suggesting that only up to 20% of patients with bipolar depression benefit from long-term treatment with antidepressants. Or conversely, up to 80% of patients with bipolar depression do not need and do not benefit from longterm antidepressant treatment.
Further, venlafaxine appeared to demonstrate higher acute manic switch rates than bupropion or sertraline. Also, these are the first randomized data with sertraline in bipolar depression (previous studies of serotonin reuptake inhibitors had mainly looked at paroxetine), and these data are somewhat reassuring that sertraline is not markedly high in its acute manic switch risk. Lastly, these data confirm the previous small dataset on bupropion in bipolar depression (n = 15),18 and validate the clinical practice of using bupropion preferentially in bipolar depression.
For the past 5 years, as part of the National Institute of Mental Health-sponsored Systematic Treatment Evaluation Program for Bipolar Disorder (STEP-BD), our group has been conducting a study with the same design as the Stanley Foundation antidepressant discontinuation study, except that our design is randomized (although not double-blind). Thus, in this study, patients who respond initially to antidepressants plus mood stabilizers are randomly selected to either continue to take the combination or discontinue the antidepressant. Patients are followed up for 1 year.
In a preliminary analysis of 69 patients,19 our primary outcome showed similar mood morbidity in both groups, indicating no added benefit with the antidepressant. In a priori secondary outcomes, there is increased mood cycling with the antidepressant group, which is a randomized confirmation that antidepressants actually worsen the long-term course of BD.
Furthermore, in the rapid-cycling subgroup, antidepressants were associated with worsened mood morbidity, primarily with more depressive symptoms. This again confirms the only earlier randomized study of the association of antidepressants with worsening of rapid cycling.20 Our study was analyzed in interim fashion this past year when it was near completion of enrollment; however, remaining patients will continue to be monitored for another year before a final analysis and publication of these data can be completed.
|Author||Number||Bipolar disorder type||Drugs||Duration of Study||Outcomes|
|Altshuler 2003||84||I and II||Antidepres- sant + mood stabilizer||At least 60 d||Longer period of antidepres- sant exposure associated with longer time before depressive relapse|
|Gijsman 2004*||779||I||Fluoxetine + olanzapine vs placebo + olanzapine|
|Fluoxetine vs placebo||7.7 wk (mean)||Antidepres- sants 1.9 times more effective than placebo, but added little to lithium alone|
|Leverich 2006||175||I and II||Venlafaxine vs sertraline vs bupropion||Up to 1 y||Similar efficacy in all groups; higher manic switch rates over 1 y with venlafaxine|
|Ghaemi 2005||69||I and II||Antidepres- sant + mood stabilizer vs mood stabilizer alone||Up to 3 y (mean, 11 mo)||Similar mood morbidity in both groups; no benefit with antidepressant continuation|
Thus, 2 recent studies of antidepressant use in BD seem to indicate benefit and 2 do not. We have suggested that the conflicting findings can partly be attributed to methodologic differences among studies. Our conclusions, based on these considerations, are that antidepressants may be more effective than no treatment for acute bipolar depression, but they may not be more effective than a mood stabilizer such as lithium. Furthermore, they have probable risks of acute mania and long-term rapid cycling. New randomized data suggest that antidepressants are notably effective in only perhaps 15% to 20% of patients with BD in the long term, and that, in particular, they likely lead to a worsened course of illness in those with rapid-cycling BD.
For the practicing clinician, we interpret these data as being consistent with the need for increased caution in the use of these agents in BD, especially for maintenance treatment, although clinicians should not avoid them altogether in the small subgroup that might benefit from them. From a public health perspective, since antidepressants are extensively used in patients with BD, we continue to see the emerging data about these agents as consistent with the need to reduce their use in this population.
Dr Ghaemi is director of the bipolar disorder research program and associate professor of psychiatry at Emory University School of Medicine in Atlanta. Ms Filkowski is research coordinator in the bipolar disorder research program at Emory University School of Medicine. The authors report no conflicts regarding the subject matter of this article.
Fakhry M. Averroes: His Life, Work, and Influence. Oxford, UK: Oxford University Press; 2001.
Soldani F, Ghaemi SN, Baldessarini R. Research methods in psychiatric treatment studies: critique and proposals. Acta Psychiatr Scand. 2005;112:1-3.
Ghaemi SN, Sachs GS, Chiou AM, et al. Is bipolar disorder still underdiagnosed? Are antidepressants overutilized? J Affect Disord. 1999;52:135-144.
Moller HJ, Grunze H. Have some guidelines for the treatment of acute bipolar depression gone too far in the restriction of antidepressants? Eur Arch Psychiatry Clin Neurosci. 2000;250:57-68.
Ghaemi SN, Hsu DJ, Soldani F, Goodwin FK. Antidepressants in bipolar disorder: the case for caution. Bipolar Disord. 2003;5:421-433.
Goldberg JF, Ghaemi SN. Benefits and limitations of antidepressants and traditional mood stabilizers for treatment of bipolar depression. Bipolar Disord. 2005;7(suppl 5):3-12.
Gray G. Evidence-based medicine: an introduction for psychiatrists. J Psychiatr Pract. 2002;8:5-13.
Miettinen OS, Cook EF. Confounding: essence and detection. Am J Epidemiol. 1981;114:593-603.
Altshuler L, Suppes T, Black D, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry. 2003;160:1252-1262.
Young LT, Joffe RT, Robb JC, et al. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am J Psychiatry. 2000;157:124-126.
Joffe RT, MacQueen GM, Marriott M, et al. Oneyear outcome with antidepressant treatment of bipolar depression. Acta Psychiatr Scand. 2005;112: 105-109.
Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537-1547.
Nemeroff CB, Evans DL, Gyulai L, et al. Doubleblind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906-912.
Cohn JB, Collins G, Ashbrook E, Wernicke JF. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol. 1989;4:313-322.
Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
Ghaemi SN, Lenox MS, Baldessarini RJ. Effectiveness and safety of long-term antidepressant treatment in bipolar disorder. J Clin Psychiatry. 2001; 62:565-569.
Leverich GS, Altshuler LL, Frye MA, et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006;163:232-239.
Sachs GS, Lafer B, Stoll AL, et al. A double-blind trial of bupropion versus desipramine for bipolar depression. J Clin Psychiatry. 1994;55:391-393.
Ghaemi SN, El-Mallakh RS, Baldassano CF, et al. A randomized clinical trial of efficacy and safety of long-term antidepressant use in bipolar disorder. Bipolar Disord. 2005;7(suppl 2):59. Abstract.
Wehr TA, Sack DA, Rosenthal NE, Cowdry RW. Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients. Am J Psychiatry. 1988;145:179-184.